For the sake of correctness, I believe you are not using the correct NTT numbers from R-I:
“Discussion In this prespecified analysis of the 3146 patients enrolled into REDUCE-IT in the United States, for the primary composite end point there was a 31% relative risk reduction and 6.5% absolute risk reduction in first ischemic events (NNT, 15). The key secondary composite end point of cardiovascular death, nonfatal MI, or nonfatal stroke was also reduced by 31%, with a 4.6% absolute risk reduction (NNT, 22). Significant reductions in all composite and individual end points in the prespecified testing hierarchy were also observed, including cardiovascular death, MI, stroke, coronary revascularization, or hospitalization for unstable angina, as was the case with the overall trial results. In the US subgroup, there was an important, significant (P=0.004) 30% relative and 2.6% absolute risk reduction in all-cause mortality (NNT, 39), with an interaction P value of 0.02 between the US and non-US subgroups.”